Treatment can be difficult for this type of breast cancer. Without receptors, triple negative tumors do not have the proteins they need to respond to common breast cancer treatments like hormone and targeted therapy, which are used for hormone-positive or HER2-positive breast cancer. Research shows that some people have a greater chance of developing triple-negative breast cancer (TNBC) if they are subject to certain risk factors. 

There was an abundance of promising new research that came out of the 2023 San Antonio Breast Cancer Symposium. Here are some highlights for metastatic breast cancer. Be sure to check out our early-stage highlights.

CBCN had the pleasure of attending the San Antonio Breast Cancer Symposium in December. Below you’ll find the latest research for early-stage breast cancer. Watch out for the latest research on mBC.

In 2023, our most read blog posts reflect the interest that patients have in connecting with others, seeking support, and sharing experiences and personal stories. Diagnoses at a young age, parenting with breast cancer, living with mBC, and other personal stories made up most of our list. Lifestyle, the latest research, and different options for reconstruction fill out the topics that our readers were most interested in last year. Here CBCN presents our top 10 blog posts from 2023.

CBCN had the opportunity to attend the ABC7 conference in Lisbon, Portugal from November 9 to 11, 2023. Here are some highlights from the conference.

The European Society of Medical Oncology held their annual congress in Madrid, Spain from October 20-24, 2023. Members of the CBCN team had the opportunity to attend and learn about the latest research to be announced for breast cancer. Here are some of those highlights.

Haven is a patient support program by Sentrex that specializes in oncology; this means our all our staff have oncology expertise. In fact, all Haven’s staff have joined Sentrex from hospital cancer centres. Haven offers certain patient support such as insurance reimbursement assistance and pharmacy services.

According to research from the National Cancer Institute, the number of women being diagnosed with metastatic breast cancer is increasing; at the same time, these women are living longer, especially younger women. Living longer with metastatic breast cancer, a stage of breast cancer which is driven in part by out-of-control production of proteins by cancerous cells, means increased needs for services and research.

In May 2021, The Dr. Susan Love Foundation, one of the top breast cancer research organizations in the United States, announced that every year, August 18^th would be known as World Breast Cancer Research Day. The 18^th was chosen as a representation of the 1 in 8 women who will be diagnosed with breast cancer during their lifetime. The Foundation also wanted the day to be apart from Breast Cancer Awareness month, which is October, as awareness, patient support, and research need to be highlighted throughout the year. Dr. Susan Love, founder of the Dr. Susan Love Foundation, recently passed away from recurrent leukemia on July 2, 2023. She was a pioneering breast cancer researcher, advocate, surgeon, and fierce critic of the medical field’s historically patriarchal system and paternalistic treatment of women.

Neutropenia is a condition caused by lower-than-normal amounts of neutrophils, a type of white blood cell. Neutrophils fight infection in the body by killing harmful bacteria and other blood-borne pathogens. The most common cause of neutropenia during breast cancer treatment is chemotherapy, though other types of cancer medicine can also cause it. Chemotherapy can cause neutropenia because it kills rapidly dividing cells, such as cancer cells. It can also affect other quickly dividing cells in our bodies, including white blood cells, red blood cells, and platelets. When chemotherapy destroys too many white blood cells, neutropenia occurs.